MX2018012700A - Semaglutida en afecciones cardiovasculares. - Google Patents
Semaglutida en afecciones cardiovasculares.Info
- Publication number
- MX2018012700A MX2018012700A MX2018012700A MX2018012700A MX2018012700A MX 2018012700 A MX2018012700 A MX 2018012700A MX 2018012700 A MX2018012700 A MX 2018012700A MX 2018012700 A MX2018012700 A MX 2018012700A MX 2018012700 A MX2018012700 A MX 2018012700A
- Authority
- MX
- Mexico
- Prior art keywords
- semaglutide
- cardiovascular conditions
- cardiovascular
- conditions
- glp
- Prior art date
Links
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 title abstract 2
- 229950011186 semaglutide Drugs 0.000 title abstract 2
- 108010060325 semaglutide Proteins 0.000 title abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 title 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16167458 | 2016-04-28 | ||
| EP16188262 | 2016-09-12 | ||
| PCT/EP2017/060160 WO2017186896A1 (en) | 2016-04-28 | 2017-04-28 | Semaglutide in cardiovascular conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018012700A true MX2018012700A (es) | 2019-01-30 |
Family
ID=58668875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012700A MX2018012700A (es) | 2016-04-28 | 2017-04-28 | Semaglutida en afecciones cardiovasculares. |
Country Status (24)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2768283C2 (ru) * | 2016-04-28 | 2022-03-23 | Ново Нордиск А/С | Семаглутид при сердечно-сосудистых состояниях |
| TWI847306B (zh) | 2017-08-24 | 2024-07-01 | 丹麥商諾佛 儂迪克股份有限公司 | Ｇｌｐ-１組成物及其用途 |
| HRP20230929T1 (hr) * | 2018-10-26 | 2023-11-24 | Novo Nordisk A/S | Stabilni pripravci semaglutida i njihova upotreba |
| ES2994462T3 (en) * | 2018-12-21 | 2025-01-24 | Novo Nordisk As | Process of spray drying of glp-1 peptide |
| PE20230819A1 (es) * | 2020-02-18 | 2023-05-19 | Novo Nordisk As | Composiciones y usos de glp-1 |
| CN114699510B (zh) * | 2021-12-29 | 2024-07-16 | 浙江湃肽生物有限公司 | 一种司美格鲁肽微针阵列及其制备方法 |
| AU2023285400A1 (en) * | 2022-06-08 | 2024-12-05 | Zydus Lifesciences Limited | Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management |
| CN117462654A (zh) * | 2023-09-28 | 2024-01-30 | 武汉大学人民医院（湖北省人民医院） | 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003084563A1 (en) * | 2002-04-04 | 2003-10-16 | Novo Nordisk A/S | Glp-1 agonist and cardiovascular complications |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| CN107961377B (zh) * | 2010-05-05 | 2022-11-22 | 勃林格殷格翰国际有限公司 | 组合疗法 |
| PT2651398T (pt) * | 2010-12-16 | 2018-03-09 | Novo Nordisk As | Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| JP6126097B2 (ja) * | 2011-09-06 | 2017-05-10 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体 |
| WO2015071355A1 (en) * | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| RU2768283C2 (ru) | 2016-04-28 | 2022-03-23 | Ново Нордиск А/С | Семаглутид при сердечно-сосудистых состояниях |
-
2017
- 2017-04-28 RU RU2018140900A patent/RU2768283C2/ru active
- 2017-04-28 CN CN201780026303.2A patent/CN109069589B/zh active Active
- 2017-04-28 SI SI201731219T patent/SI3448416T1/sl unknown
- 2017-04-28 EP EP17721109.1A patent/EP3448416B1/en active Active
- 2017-04-28 MA MA044762A patent/MA44762A/fr unknown
- 2017-04-28 PL PL17721109.1T patent/PL3448416T3/pl unknown
- 2017-04-28 ES ES17721109T patent/ES2928007T3/es active Active
- 2017-04-28 JP JP2018556411A patent/JP7221694B2/ja active Active
- 2017-04-28 HU HUE17721109A patent/HUE060040T2/hu unknown
- 2017-04-28 MX MX2018012700A patent/MX2018012700A/es unknown
- 2017-04-28 CA CA3022535A patent/CA3022535A1/en active Pending
- 2017-04-28 WO PCT/EP2017/060160 patent/WO2017186896A1/en not_active Ceased
- 2017-04-28 KR KR1020257007151A patent/KR20250038818A/ko active Pending
- 2017-04-28 BR BR112018072020-8A patent/BR112018072020A2/pt unknown
- 2017-04-28 KR KR1020227036550A patent/KR102778218B1/ko active Active
- 2017-04-28 DK DK17721109.1T patent/DK3448416T3/da active
- 2017-04-28 MY MYPI2018703725A patent/MY202967A/en unknown
- 2017-04-28 AU AU2017256774A patent/AU2017256774B2/en active Active
- 2017-04-28 KR KR1020187033310A patent/KR20180135012A/ko not_active Ceased
- 2017-04-28 HR HRP20221150TT patent/HRP20221150T1/hr unknown
- 2017-04-28 PH PH1/2018/502274A patent/PH12018502274B1/en unknown
- 2017-04-28 RS RS20220901A patent/RS63630B1/sr unknown
- 2017-04-28 US US16/097,032 patent/US20190134162A1/en active Pending
-
2018
- 2018-10-15 IL IL262390A patent/IL262390B1/en unknown
- 2018-10-25 CL CL2018003045A patent/CL2018003045A1/es unknown
-
2024
- 2024-10-04 AU AU2024227113A patent/AU2024227113A1/en active Pending
-
2025
- 2025-01-15 US US19/023,039 patent/US20250288649A1/en active Pending
- 2025-05-02 US US19/197,677 patent/US20250262281A1/en active Pending
- 2025-09-03 ZA ZA2025/07395A patent/ZA202507395B/en unknown
- 2025-09-03 ZA ZA2025/07394A patent/ZA202507394B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202507395B (en) | Semaglutide in cardiovascular conditions | |
| ZA201904616B (en) | Glp-1 receptor agonists and uses thereof | |
| MX2020014121A (es) | Agonistas parciales del receptor de insulina. | |
| MX2018005132A (es) | Agonistas del receptor de glucagon. | |
| PH12016501700A1 (en) | Combination therapies with anti-cd38 antibodies | |
| IL251027A0 (en) | History of pyrrolopyrimidines as nr2b nmda receptor antagonists | |
| WO2017100107A3 (en) | Co-agonists of the glucagon and glp-1 receptors | |
| MX2016015631A (es) | Nuevos compuestos. | |
| PH12018501844B1 (en) | Liraglutide in cardiovascular conditions | |
| PH12016500044A1 (en) | Vasopressin-2 receptor agonists | |
| GB201513543D0 (en) | Compositions for use in the treatment of diabetes | |
| UA92304U (ru) | Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства противодиабетического действия для терапии инсулиннезависимого сахарного диабета | |
| PH12014000104A1 (en) | Therapeutic methods and compositions for treating diabetes | |
| IN2014CH01195A (cg-RX-API-DMAC7.html) | ||
| UA88242U (ru) | Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства гипогликемического действия |